February 11, 2020 / 11:52 AM / 6 days ago

BRIEF-Brainstorm Cell Therapeutics And FDA Agree To Potential Nurown Regulatory Pathway For Approval In Als

Feb 11 (Reuters) - Brainstorm Cell Therapeutics Inc :

* BRAINSTORM CELL THERAPEUTICS AND FDA AGREE TO POTENTIAL NUROWN® REGULATORY PATHWAY FOR APPROVAL IN ALS

* BRAINSTORM CELL THERAPEUTICS - FDA CONFIRMED FULLY ENROLLED PHASE 3 ALS TRIAL IS COLLECTING RELEVANT DATA CRITICAL TO ASSESSMENT OF NUROWN EFFICACY

* BRAINSTORM CELL THERAPEUTICS INC - FDA INDICATED THEY WILL LOOK AT “TOTALITY OF EVIDENCE” IN EXPECTED PHASE 3 CLINICAL TRIAL DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below